Involvement of substance P in peripheral neuropathy induced by paclitaxel but not oxaliplatin

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 1, 2011, Pages 226-235

  Tatsushima, Yoko ^a   Egashira, Nobuaki ^a   Kawashiri, Takehiro ^a   Mihara, Yuki ^a   Yano, Takahisa ^a   Mishima, Kazuto ^a   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 3 [2 [4 METHOXY 4 [(PHENYLSULFINYL)METHYL] 1 PIPERIDINYL]ETHYL] 1H INDOLE; ELPLAT; GR 159897; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; OXALIPLATIN; PACLITAXEL; PEMIROLAST; SUBSTANCE P; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HORMONE RELEASE; HYPERALGESIA; IN VITRO STUDY; MALE; NERVE CELL CULTURE; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SPINAL GANGLION;

ANIMALS; CELLS, CULTURED; GANGLIA, SPINAL; MALE; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE P;

EID: 79953004597     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.175976     Document Type: Article

References (40)

1. Apfel SC, Lipton RB, Arezzo JC, and Kessler JA (1991) Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 29:87-90.
2. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, Iconomou G, and Kalofonos HP (2005) Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64:26-31. (Pubitemid 40082932)
3. Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, and Gianni L (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746-1750. (Pubitemid 41132636)
4. Cahill CM and Coderre TJ (2002) Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre- or post-treatment with a neurokinin-1 antagonist. Pain 95:277-285. (Pubitemid 34142651)
5. Cavaletti G, Tredici G, Petruccioli MG, Dondè E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, and Etienne GG (2001) Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37:2457-2463.
6. Chaplan SR, Bach FW, Pogrel JW, Chung JM, and Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63. (Pubitemid 24238751)
7. Coudoré-Civiale M, Courteix C, Boucher M, Fialip J, and Eschalier A (2000) Evidence for an involvement of tachykinins in allodynia in streptozocin-induced diabetic rats. Eur J Pharmacol 401:47-53. (Pubitemid 30479811)
8. De Koninck Y and Henry JL (1991) Substance P-mediated slow excitatory postsynaptic potential elicited in dorsal horn neurons in vivo by noxious stimulation. Proc Natl Acad Sci USA 88:11344-11348. (Pubitemid 21916037)
9. Dionne RA, Max MB, Gordon SM, Parada S, Sang C, Gracely RH, Sethna NF, and MacLean DB (1998) The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 64:562-568. (Pubitemid 28531601)
10. Dixon WJ (1980) Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20:441-462.
11. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, et al. (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132:237-251. (Pubitemid 350051570)
12. Flatters SJ and Bennett GJ (2004) Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 109:150-161. (Pubitemid 38479781)
13. Fujimiya H, Nakashima S, Kumada T, Nakamura Y, Miyata H, and Nozawa Y (1994) An antiallergic drug, pemirolast potassium, inhibits inositol 1,4,5-trisphosphate production and Ca2+ mobilization in antigen-stimulated rat basophilic leukemia (RBL-2H3) cells. Arerugi 43:142-151. (Pubitemid 24097006)
14. Gamelin E, Gamelin L, Bossi L, and Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29(Suppl 15):21-33. (Pubitemid 35191038)
15. Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, and de Gramont A (2008) Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 26:1188-1189; author reply 1189-1190.
16. Goff JR, Burkey AR, Goff DJ, and Jasmin L (1998) Reorganization of the spinal dorsal horn in models of chronic pain: correlation with behaviour. Neuroscience 82:559-574. (Pubitemid 27461640)
17. 1 receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 294:444-450.
18. Harrison S and Geppetti P (2001) Substance P. Int J Biochem Cell Biol 33:555-576. (Pubitemid 32510811)
19. Itoh Y, Sendo T, Hirakawa T, Goromaru T, Takasaki S, Yahata H, Nakano H, and Oishi R (2004a) Role of sensory nerve peptides rather than mast cell histamine in paclitaxel hypersensitivity. Am J Respir Crit Care Med 169:113-119. (Pubitemid 38233897)
20. Itoh Y, Sendo T, Hirakawa T, Takasaki S, Goromaru T, Nakano H, and Oishi R (2004b) Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. Neuropharmacology 46:888-894. (Pubitemid 38368921)
21. Jamieson SM, Liu J, Connor B, and McKeage MJ (2005) Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 56:391-399. (Pubitemid 41095402)
22. Kawashiri T, Egashira N, Itoh Y, Shimazoe T, Ikegami Y, Yano T, Yoshimura M, and Oishi R (2009) Neurotropin reverses paclitaxel-induced neuropathy without affecting anti-tumour efficacy. Eur J Cancer 45:154-163.
23. Lee JJ and Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633-1642. (Pubitemid 46638788)
24. Ling B, Authier N, Balayssac D, Eschalier A, and Coudore F (2007) Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 128:225-234. (Pubitemid 46389544)
25. Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau' F, et al. (2003) Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 14:1086-1093. (Pubitemid 36950173)
26. Luo FR, Wyrick SD, and Chaney SG (1999) Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol 44:29-38. (Pubitemid 29246322)
27. McKeage MJ, Hsu T, Screnci D, Haddad G, and Baguley BC (2001) Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 85:1219-1225. (Pubitemid 33052324)
28. Miyano K, Tang HB, Nakamura Y, Morioka N, Inoue A, and Nakata Y (2009) Paclitaxel and vinorelbine, evoked the release of substance P from cultured rat dorsal root ganglion cells through different PKC isoform-sensitive ion channels. Neuropharmacology 57:25-32.
29. Otsuka M and Yoshioka K (1993) Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73:229-308. (Pubitemid 23119035)
30. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY, et al. (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110-2118. (Pubitemid 350036873)
31. Regoli D, Drapeau G, Dion S, and Couture R (1988) New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol Sci 9:290-295.
32. Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H, and Oishi R (2009) Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain 147:165-174.
33. Sendo T, Itoh Y, Goromaru T, Hirakawa T, Ishida M, Nakano H, and Oishi R (2004) Role of substance P in hypersensitivity reactions induced by paclitaxel, an anticancer agent. Peptides 25:1205-1208. (Pubitemid 38881661)
34. Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, and Gooch CL (2005) Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 17:271-276. (Pubitemid 40716452)
35. Ta LE, Espeset L, Podratz J, and Windebank AJ (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27:992-1002. (Pubitemid 44838955)
36. Takeda K, Negoro S, and Matsui K (2002) Phase I safety and pharmacokinetic trial of BNP7787 in patients receiving cisplatin (CDDP) and paclitaxel (PTX) for advanced non-small cell lung cancer (NSCLC): An Osaka phase I study group trial. Proc Am Soc Clin Oncol 21:114.
37. Vachon P, Massé R, and Gibbs BF (2004) Substance P and neurotensin are upregulated in the lumbar spinal cord of animals with neuropathic pain. Can J Vet Res 68:86-92. (Pubitemid 38735682)
38. Vedder H and Otten U (1991) Biosynthesis and release of tachykinins from rat sensory neurons in culture. J Neurosci Res 30:288-299.
39. Yahata H, Saito M, Sendo T, Itoh Y, Uchida M, Hirakawa T, Nakano H, and Oishi R (2006) Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. Int J Cancer 118:2636-2638.
40. Yanagihara Y, Kasai H, and Shida T (1988) Immunopharmacological studies on TBX, a new antiallergic drug (2). Inhibitory effects on histamine release from peritoneal mast cells and lung fragments of rats. Jpn J Pharmacol 48:103-112.